Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033208 | 1.00 | MEN1 (0.51) | MEN1KMT2AHSD17B10HTTCASR | |
| SCHEMBL3435521 | 0.96 | MEN1 (0.48) | MEN1KMT2ACASR | |
| SCHEMBL249390 | 0.96 | MEN1 (0.48) | MEN1KMT2ACASR | |
| SCHEMBL3435870 | 0.96 | MEN1 (0.48) | MEN1KMT2ACASR | |
| SCHEMBL6023367 | 0.80 | TSHR (0.44) | ALDH1A1 | |
| SCHEMBL18272282 | 0.79 | EPHX1 (0.47) | HSD17B10NPC1 | |
| SCHEMBL28338185 | 0.79 | EPHX1 (0.47) | HSD17B10NPC1 | |
| SCHEMBL28369492 | 0.77 | MEN1 (0.45) | MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL17972913 | 0.77 | MEN1 (0.45) | MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL18272207 | 0.77 | ALDH1A1 (0.50) | MEN1KMT2AHSD17B10CASRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2810927-A1 | Therapeutic compounds | Sowood Healthcare LLC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8871815-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140206773-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2301908-B1 | (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect, treatment of nausea and vomiting and treatment of migraine | SIGNATURE THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8575400-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130059919-A1 | Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2013-03-07 | — | — | US | disclosed |
| US-8242315-B2 | Stereoisomers propofol therapeutic compounds | Singature Therapeutics, Inc. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120035271-A1 | Stereoisomers Propofol Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8071818-B2 | Therapeutic compounds | PHARMACOFORE, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2301908-A1 | (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect and treatment of nausea and vomiting | Pharmacofore, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2292577-A1 | (+)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof | Pharmacofore, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100292346-A1 | Stereoisomers Propofol Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2010-11-18 | — | — | US | disclosed |
| EP-2146946-B1 | (-)- stereoisomer of 2,6-di-sec-butylphenol and analogs thereof | PHARMACOFORE INC (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-2146946-A2 | STEREOISOMERIC PROPOFOL THERAPEUTIC COMPOUNDS | Pharmacofore, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008141097-A2 | STEREOISOMERS PROPOFOL THERAPEUTIC COMPOUNDS | PHARMACOFORE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059919-A1 | Therapeutic Compounds | SCN1B, ABCB11, SLC10A1 | MEN1 1249/4885KMT2A 3757/4885HSD17B10 609/4885 |
| US-20100292346-A1 | Stereoisomers Propofol Therapeutic Compounds | GABRP, OPRM1, OPRD1 | MEN1 3223/4885KMT2A 3068/4885HSD17B10 670/4885 |
| US-20140206773-A1 | Therapeutic Compounds | OPRM1, OGFR, OPRD1 | MEN1 2062/4885KMT2A 3053/4885HSD17B10 813/4885 |
| US-20120035271-A1 | Stereoisomers Propofol Therapeutic Compounds | GABRP, OPRM1, OPRD1 | MEN1 3223/4885KMT2A 3068/4885HSD17B10 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.